Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria

The Lancet Oncology

Volumn 15, Issue 13, 2014, Pages e606-e619

  Ruhnke, Markus ^a   Arnold, Renate ^b   Gastmeier, Petra ^b,c  

^a Paracelsus Hospital Osnabrück   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c University Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLAVULANIC ACID; COLISTIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERTAPENEM; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METICILLIN; MOXIFLOXACIN; PENICILLIN DERIVATIVE; POLYMYXIN; POLYPEPTIDE ANTIBIOTIC AGENT; SULTAMICILLIN; TICARCILLIN; TIGECYCLINE; TIMENTIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTI INFECTIVE STEWARDSHIP; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIUM IDENTIFICATION; BLOODSTREAM INFECTION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CRITICALLY ILL PATIENT; DRUG USE; ENTEROCOCCUS FAECIUM; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FOOD CONTAMINATION; GRANULOCYTOPENIA; HEALTH CARE COST; HEALTHCARE ASSOCIATED INFECTION; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR PATHOLOGY; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PYREXIA IDIOPATHICA; REVIEW; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS; BACTERIUM; DRUG EFFECTS; HEMATOLOGIC NEOPLASMS; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HEMATOLOGIC NEOPLASMS; HUMANS; INFECTION CONTROL;

EID: 84925230536     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70344-4     Document Type: Review

References (98)

1. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011, 52:e56-e93.
2. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003, 36:1103-1110.
3. Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007, 30(suppl 1):S51-S59.
4. Gudiol C, Bodro M, Simonetti A, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect 2013, 19:474-479.
5. Gudiol C, Tubau F, Calatayud L, et al. Bacteraemia due to multidrug-resistant gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 2011, 66:657-663.
6. Ramphal R Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 2004, 39(suppl 1):S25-S31.
7. Cattaneo C, Quaresmini G, Casari S, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 2008, 61:721-728.
8. Chen CY, Tsay W, Tang JL, et al. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect 2010, 138:1044-1051.
9. Trecarichi EM, Tumbarello M, Caira M, et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica 2011, 96:e1-e3.
10. Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013, 98:1826-1835.
11. Averbuch D, Cordonnier C, Livermore DM, et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica 2013, 98:1836-1847.
12. Hrabak J, Chudackova E, Walkova R Matrix-assisted laser desorption ionization-time of flight (Maldi-TOF) mass spectrometry for detection of antibiotic resistance mechanisms: from research to routine diagnosis. Clin Microbiol Rev 2013, 26:103-114.
13. Bush K Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr Opin Microbiol 2010, 13:558-564.
14. Jacoby GA, Munoz-Price LS The new β-lactamases. N Engl J Med 2005, 352:380-391.
15. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010, 10:597-602.
16. Galan JC, Gonzalez-Candelas F, Rolain JM, Canton R Antibiotics as selectors and accelerators of diversity in the mechanisms of resistance: from the resistome to genetic plasticity in the beta-lactamases world. Front Microbiol 2013, 4:9.
17. Rice LB Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008, 197:1079-1081.
18. Peterson LR Bad bugs, no drugs: no ESCAPE revisited. Clin Infect Dis 2009 15, 49:992-993.
19. Antimicrobial resistance surveillance in Europe2011 2013, European Centre for Disease Prevention and Control, EDEC, Stockholm, (accessed Aug 26, 2013). http://www.ecdc.europa.eu/en/publications/Publications/1111_SUR_AMR_data.pdf.pdf.
20. Antibiotic resistance threats in the United States US Department of Health and Human Services Centers for Disease Control and Prevention, (accessed Sept 15, 2013). http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf.
21. Tacconelli E, Cataldo MA, Dancer SJ, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 2014, 20(suppl):1-55.
22. Schlesinger A, Paul M, Gafter-Gvili A, Rubinovitch B, Leibovici L Infection-control interventions for cancer patients after chemotherapy: a systematic review and meta-analysis. Lancet Infect Dis 2009, 9:97-107.
23. Suarez C, Pena C, Arch O, et al. A large sustained endemic outbreak of multiresistant Pseudomonas aeruginosa: a new epidemiological scenario for nosocomial acquisition. BMC Infect Dis 2011, 11:272.
24. Kaier K, Wilson C, Hulscher M, et al. Implementing strategic bundles for infection prevention and management. Infection 2012, 40:225-228.
25. Kamboj M, Chung D, Seo SK, et al. The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant 2010, 16:1576-1581.
26. Weinstock DM, Conlon M, Lovino C, et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2007, 13:615-621.
27. Avery R, Kalaycio M, Pohlman B, Sobecks R, et al. Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant 2005, 35:497-499.
28. Taur Y, Xavier JB, Lipuma L, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012, 55:905-914.
29. Taur Y, Pamer EG The intestinal microbiota and susceptibility to infection in immunocompromised patients. Curr Opin Infect Dis 2013, 26:332-337.
30. Zirakzadeh A, Gastineau DA, Mandrekar JN, Burke JP, Johnston PB, Patel R Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2008, 41:385-392.
31. Matar MJ, Tarrand J, Raad I, Rolston KV Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer. Am J Infect Control 2006, 34:534-536.
32. Grabsch EA, Mahony AA, Cameron DR, et al. Significant reduction in vancomycin-resistant enterococcus colonization and bacteraemia after introduction of a bleach-based cleaning-disinfection programme. J Hosp Infect 2012, 82:234-242.
33. Pottinger PS Methicillin-resistant StaphylococcuS aureus infections. Med Clin North Am 2013, 97:601-619.
34. Quilty S, Kwok G, Hajkowicz K, Currie B High incidence of methicillin-resistant Staphylococcus aureus sepsis and death in patients with febrile neutropenia at Royal Darwin Hospital. Intern Med J 2009, 39:557-559.
35. Shaw BE, Boswell T, Byrne JL, Yates C, Russell NH Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak. Bone Marrow Transplant 2007, 39:623-629.
36. Humphreys H, Grundmann H, Skov R, Lucet JC, Cauda R Prevention and control of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2009, 15:120-124.
37. van der ZA, Hendriks WD, Roorda L, Ossewaarde JM, Buitenwerf J Review of a major epidemic of methicillin-resistant Staphylococcus aureus: the costs of screening and consequences of outbreak management. Am J Infect Control 2013, 41:204-209.
38. Shenoy ES, Kim J, Rosenberg ES, et al. Discontinuation of contact precautions for methicillin-resistant Staphylococcus aureus: a randomized controlled trial comparing passive and active screening with culture and polymerase chain reaction. Clin Infect Dis 2013, 57:176-184.
39. Fuller C, Robotham J, Savage J, et al. The national one week prevalence audit of universal meticillin-resistant Staphylococcu aureus (MRSA) admission screening 2012. PLoS One 2013, 8:e74219.
40. Kang CI, Chung DR, Ko KS, Peck KR, Song JH Risk factors for infection and treatment outcome of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol 2012, 91:115-121.
41. Gudiol C, Calatayud L, Garcia-Vidal C, et al. Bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 2010, 65:333-341.
42. Leistner R, Meyer E, Gastmeier P, et al. Risk factors associated with the community-acquired colonization of extended-spectrum β-lactamase (ESBL) positive Escherichia coli. An exploratory case-control study. PLoS One 2013, 8:e74323.
43. Meyer E, Gastmeier P, Kola A, Schwab F Pet animals and foreign travel are risk factors for colonisation with extended-spectrum β-lactamase-producing Escherichia coli. Infection 2012, 40:685-687.
44. Paltansing S, Vlot JA, Kraakman ME, et al. Extended-spectrum β-lactamase-producing enterobacteriaceae among travelers from the Netherlands. Emerg Infect Dis 2013, 19:1206-1213.
45. Kluytmans JA, Overdevest IT, Willemsen I, et al. Extended-spectrum β-lactamase-producing Escherichia coli from retail chicken meat and humans: comparison of strains, plasmids, resistance genes, and virulence factors. Clin Infect Dis 2013, 56:478-487.
46. Lyytikainen O, Golovanova V, Kolho E, et al. Outbreak caused by tobramycin-resistant Pseudomonas aeruginosa in a bone marrow transplantation unit. Scand J Infect Dis 2001, 33:445-449.
47. Mudau M, Jacobson R, Minenza N, et al. Outbreak of multi-drug resistant Pseudomonas aeruginosa bloodstream infection in the haematology unit of a South African Academic Hospital. PLoS One 2013, 8:e55985.
48. Trecarichi EM, Tumbarello M, Caira M, et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica 2011, 96:e1-e3.
49. Howard A, O'Donoghue M, Feeney A, Sleator RD Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence 2012 1, 3:243-250.
50. Sood P, Seth T, Kapil A, et al. Emergence of multidrug resistant acinetobacter blood stream infections in febrile neutropenia patients with haematological cancers and bone marrow failure syndromes. J Indian Med Assoc 2012, 110:439-444.
51. Irfan S, Idrees F, Mehraj V, Habib F, Adil S, Hasan R Emergence of carbapenem resistant gram negative and vancomycin resistant gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study. BMC Infect Dis 2008, 8:80.
52. Metan G, Demiraslan H, Kaynar LG, Zararsiz G, Alp E, Eser B Factors influencing the early mortality in haematological malignancy patients with nosocomial gram negative bacilli bacteraemia: a retrospective analysis of 154 cases. Braz J Infect Dis 2013, 17:143-149.
53. Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2012, 1. CD004386.
54. Adriaenssens N, Coenen S, Versporten A, et al. European Surveillance of antimicrobial consumption (ESAC): outpatient quinolone use in Europe (1997-2009). J Antimicrob Chemother 2011, 66(suppl 6):vi47-vi56.
55. Ng ES, Liew Y, Earnest A, Koh LP, Lim SW, Hsu LY Audit of fluoroquinolone prophylaxis against chemotherapy-induced febrile neutropenia in a hospital with highly prevalent fluoroquinolone resistance. Leuk Lymphoma 2011, 52:131-133.
56. Rangaraj G, Granwehr BP, Jiang Y, Hachem R, Raad I Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer 2010, 116:967-973.
57. Reuter S, Kern WV, Sigge A, et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 2005, 40:1087-1093.
58. Cullen M, Baijal S Prevention of febrile neutropenia: use of prophylactic antibiotics. Br J Cancer 2009, 101(suppl 1):S11-S14.
59. Neumann S, Krause SW, Maschmeyer G, Schiel X, von Lilienfeld-Toal M Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2013, 92:433-442.
60. Bucaneve G, Castagnola E, Viscoli C, Leibovici L, Menichetti F Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients. Eur J Cancer 2013, 5(suppl):5-12.
61. Leibovici L, Paul M, Cullen M, et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006, 107:1743-1751.
62. Cullen MH, Billingham LJ, Gaunt CH, Steven NM Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol 2007, 25:4821-4828.
63. de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2010, 21(suppl 5):v252-v256.
64. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000, 18:3038-3051.
65. MacDougall C, Polk RE Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 2005, 18:638-656.
66. Katsios CM, Burry L, Nelson S, et al. An antimicrobial stewardship program improves antimicrobial treatment by culture site and the quality of antimicrobial prescribing in critically ill patients. Crit Care 2012, 16:R216.
67. Arnold HM, Micek ST, Skrupky LP, Kollef MH Antibiotic stewardship in the intensive care unit. Semin Respir Crit Care Med 2011, 32:215-227.
68. Liew YX, Lee W, Loh JC, et al. Impact of an antimicrobial stewardship programme on patient safety in Singapore General Hospital. Int J Antimicrob Agents 2012, 40:55-60.
69. Chan YY, Lin TY, Huang CT, et al. Implementation and outcomes of a hospital-wide computerised antimicrobial stewardship programme in a large medical centre in Taiwan. Int J Antimicrob Agents 2011, 38:486-492.
70. Swoboda S, Lichtenstern C, Ober MC, et al. Implementation of practice guidelines for antifungal therapy in a surgical intensive care unit and its impact on use and costs. Chemotherapy 2009, 55:418-424.
71. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America, the Infectious Diseases Society of America, and the Pediatric Infectious Diseases Society. Infect Control Hosp Epidemiol 2012, 33:322-327. Society for Healthcare Epidemiology of America, Infectious Diseases Society of AmericaInfectious Diseases Society of America, Pediatric Infectious Diseases SocietyPediatric Infectious Diseases Society.
72. Drew RH, White R, MacDougall C, Hermsen ED, Owens RC Insights from the Society of Infectious Diseases Pharmacists on antimicrobial stewardship guidelines from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Pharmacotherapy 2009, 29:593-607.
73. Weber DJ Collateral damage and what the future might hold. The need to balance prudent antibiotic utilization and stewardship with effective patient management. Int J Infect Dis 2006, 10(suppl 2):S17-S24.
74. Nathwani D, Sneddon J, Malcolm W, et al. Scottish Antimicrobial Prescribing Group (SAPG): development and impact of the Scottish National Antimicrobial Stewardship Programme. Int J Antimicrob Agents 2011, 38:16-26.
75. Gyssens IC, Kern WV, Livermore DM The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients. Haematologica 2013, 98:1821-1825.
76. Perreten V, Schwarz F, Cresta L, Boeglin M, Dasen G, Teuber M Antibiotic resistance spread in food. Nature 1997, 389:801-802.
77. Jamet E, Akary E, Poisson MA, Chamba JF, Bertrand X, Serror P Prevalence and characterization of antibiotic resistant Enterococcus faecalis in French cheeses. Food Microbiol 2012, 31:191-198.
78. Remington JS, Schimpff SC Occasional notes. Please don't eat the salads. N Engl J Med 1981, 304:433-435.
79. Luo Y, Cui S, Li J, Yang J, Lin L, Hu C, et al. Characterization of Escherichia coli isolates from healthy food handlers in hospital. Microb Drug Resist 2011, 17:443-448.
80. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15:1143-1238.
81. Trifilio S, Helenowski I, Giel M, et al. Questioning the role of a neutropenic diet following hematopoetic stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:1385-1390.
82. Boeckh M Neutropenic diet--good practice or myth?. Biol Blood Marrow Transplant 2012, 18:1318-1319.
83. Szmolka A, Nagy B Multidrug resistant commensal Escherichia coli in animals and its impact for public health. Front Microbiol 2013, 4:258.
84. Kola A, Kohler C, Pfeifer Y, et al. High prevalence of extended-spectrum-β-lactamase-producing Enterobacteriaceae in organic and conventional retail chicken meat, Germany. J Antimicrob Chemother 2012, 67:2631-2634.
85. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12.
86. Climo MW, Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 2013, 368:533-542.
87. Bass P, Karki S, Rhodes D, et al. Impact of chlorhexidine-impregnated washcloths on reducing incidence of vancomycin-resistant enterococci colonization in hematology-oncology patients. Am J Infect Control 2013, 41:345-348.
88. Huang SS, Septimus E, Kleinman K, et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med 2013, 368:2255-2265.
89. Lin MY, Lolans K, Blom DW, et al. The effectiveness of routine daily chlorhexidine gluconate bathing in reducing Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae skin burden among long-term acute care hospital patients. Infect Control Hosp Epidemiol 2014, 35:440-442.
90. Lucet JC, Regnier B Screening and decolonization: does methicillin-susceptible Staphylococcus aureus hold lessons for methicillin-resistant S. aureus?. Clin Infect Dis 2010, 51:585-590.
91. Tacconelli E, De AG, Cataldo MA, Pozzi E, Cauda R Does antibiotic exposure increase the risk of methicillin-resistant StaphylococcuS aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother 2008, 61:26-38.
92. Zaas AK, Song X, Tucker P, Perl TM Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis 2002, 35:1139-1146.
93. Kuehnert MJ, Jernigan JA, Pullen AL, Rimland D, Jarvis WR Association between mucositis severity and vancomycin-resistant enterococcal bloodstream infection in hospitalized cancer patients. Infect Control Hosp Epidemiol 1999, 20:660-663.
94. Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006, 50:498-504.
95. Lin MY, Lyles-Banks RD, Lolans K, et al. the importance of long-term acute care hospitals in the regional epidemiology of Klebsiella pneumoniae carbapenemase-producing enterobacteriaceae. Clin Infect Dis 2013, 57:1246-1252.
96. Oliveira AL, de Souza M, Carvalho-Dias VM, et al. Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2007, 39:775-781.
97. Durante-Mangoni E, Zarrilli R Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance. Future Microbiol 2011, 6:407-422.
98. Wisplinghoff H, Paulus T, Lugenheim M, et al. Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States. J Infect 2012, 64:282-290.